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ABSTRACT 
Background: Left ventricular remodeling (LVR) following myocardial infarction (MI) is 
associated with an increased risk of heart failure (HF) and death. In spite of a modern therapeutic 
approach, LVR remains relatively frequent and difficult to predict in clinical practice. Our aim 
was to identify new biomarkers of LVR and understand their involvement in its development.  
Methods and Results: Proteomic analysis of plasma from the REVE-2 study – a study dedicated 
to the analysis of LVR which included 246 patients after a first anterior MI - identified increased 
plasma levels of clusterin in patients with high LVR. We used a rat model of MI to analyze 
clusterin expression in the LV and found a significant increase that was correlated with LVR 
parameters. We found increased clusterin expression and secretion in primary cultures of rat 
neonate cardiomyocytes (NCM) hypertrophied by isoproterenol. Silencing of clusterin in 
hypertrophied NCM induced a significant decrease in cell size, ANP, and BNP expression, 
associated with a decreased ERK1/2 activity, suggesting a pro-hypertrophic role of clusterin. We 
then confirmed a significant increase of both intracellular precursor and mature form of clusterin 
in failing human hearts.  Finally, the circulating levels of clusterin (secreted form) were 
increased in patients with chronic HF who died from cardiovascular cause during a 3-year 
follow-up (n=99) compared to survivors (n=99).  
Conclusions: Our results show for the first time that plasma clusterin levels are associated with 
LVR post-MI, have a part of cardiac origin and are predictor of early death in HF patients. 
CIRCHF/2017/004838-R3 
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INTRODUCTION 
Chronic heart failure (HF) remains a major public health problem
1
 with a high rate of 
mortality in spite of recent therapeutic improvements
2
. The most common cause of HF is 
coronary artery disease and particularly myocardial infarction (MI)
3
.  
Left ventricular remodeling (LVR) following myocardial infarction is a dynamic and complex 
process that occurs in response to myocardial damage and is associated with an increased risk of 
HF and cardiovascular death
4,5
. Post-MI LVR can be divided in two phases. The early phase 
(occurring few hours to several weeks after MI onset) involves the expansion of the infarct zone, 
including dilatation and thinning of the infarct zone
6
. The late phase (months, years) involves 
globally the LV and is associated with time-dependent dilatation, distortion of ventricular shape, 
mural hypertrophy, as well as structural tissue changes
7
. Although LVR may be considered as a 
protective mechanism to maintain systolic flow and cardiac “pump” function, this phenomenon 
leads to alterations of global LV function and ultimately aggravates HF. In two independent 
prospective echocardiographic studies (REmodelage VEntriculaire, REVE and REVE-2), we 
observed a 30-40% LVR rate after a first acute anterior wall MI despite high acute reperfusion 
rates and widespread prescription of secondary prevention medications
8,9
. However, LVR 
remains difficult to predict in clinical practice and its severity cannot be fully predicted based on 
its known determinants such as those related to infarct size, anterior infarct location or LV 
ejection fraction
10
. Circulating biological markers called "biomarkers" may facilitate the 
diagnosis and the prognosis of LVR and HF
11
. The only biomarker clinically used in MI patients 
is B-type natriuretic peptide (BNP) whose concentration helps to predict the risk of HF
12
, but 
data on its ability to predict LVR are discordant
9,13,14,15
.  
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Clusterin (CLU) is constitutively expressed in most mammalian tissues and is highly 
conserved across species. Several functions have been proposed for CLU such as complement 
activity regulation, lipid transport, apoptosis regulation and cell interaction
16
. Several studies 
show increased CLU levels in plasma
17,18
 and LV
18,19
 of MI patients at early stage after MI. Until 
now, the relationship of plasma CLU levels with LVR post-MI has not been studied despite a 
recent study showing that CLU is independently associated with chronic HF
20
. 
In this study, we show for the first time that 1) CLU is increased in late stage after MI and is 
associated with LVR; 2) CLU expression and secretion are increased by hypertrophied 
cardiomyocytes and seems play a pro-hypertrophic role and; 3) plasma levels of CLU are 
predictor of early death in HF patients. 
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MATERIALS AND METHODS 
Detailed information is supplied as supplemental. The data, analytic methods, and study materials 
will be been made available to other researchers for purposes of reproducing the results or 
replicating the procedure. 
Patients 
The studies were approved by the Ethics Committee of the “Centre Hospitalier et Universitaire de 
Lille” and comply with the Declaration of Helsinski. All patients gave written informed consent. 
REVE-2 study 
The design of the REVE-2 study has been published in detail elsewhere
9
. We enrolled 246 
patients with a first anterior wall Q-wave MI between February 2006 and September 2008. The 
protocol required serial echographic studies at baseline (day 3 to day 7) and 3 and 12 months 
after MI. Left ventricular remodeling (LVR) was defined as percent change in EDV from 
baseline to 1 year. Serial blood samples were taken at discharge (day 3 to day 7), and 1, 3, and 12 
months after MI. 
INCA study  
All patients referred for evaluation of systolic HF (LVEF <45%) in our institution between 
November 1998 and May 2010 were included in a prospective cohort on prognostic 
indicators
21,22,23
. From this population, we selected 198 patients included between November 
1998 and December 2005, as previously described
24
. Blood sample was obtained at inclusion. 
Human heart biopsies  
CIRCHF/2017/004838-R3 
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Tissues from failing and non-failing human hearts were obtained respectively from Lille 
University Hospital (France) and from Catholic University of Leuven (Belgium).  
Animal models 
All animal experiments were performed according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH publication NO1-
OD-4-2-139, revised in 2011). MI was induced in 10-week-old male Wistar rats (Janvier, Le 
Genest St isle, France) by ligation of the left anterior descending coronary artery 
25,26
. Sham-
operated and MI rats were then further separated in two subgroups that were sacrificed at 7 days 
(n=8/group) or 2 months (n= 9 to 11/ group) post-MI. Haemodynamic and echocardiographic 
measurements were taken 2 months after surgery, followed by heart excision, as previously 
described
27,28
. 
Cellular models 
H9C2 cells and primary cultures of neonate rat cardiomyocytes  (NCM) were prepared and 
cultured as previously described
29
. 
Proteomic analysis of plasma samples from REVE-2 patients 
Plasma samples underwent no more than two freeze/thaw cycles and were treated 
combinatorial peptide ligand library (CPLL) method to allow for the enrichment in medium- and 
low-abundance proteins
30
. 2D-DIGE electrophoresis was performed and analyzed as previously 
described
31
. Differentially regulated spots were excised manually from a preparative gel 
performed with 500 µg of proteins and in-gel digested with trypsin
32
.  
Western blot analysis 
CIRCHF/2017/004838-R3 
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The primary antibodies and dilution used for western blot analysis are detailed in the 
Supplemental Table 1).   
Quantification by multiplex immunoassay  
B-type natriuretic peptide (BNP) was measured in plasma samples using a Multi Analyte 
Profiling Kit for simultaneous quantitative detection of rat cardiovascular biomarkers (Rat CVD1 
Panel 1, RCVD1-89K Millipore) according to the manufacturer’s instructions as previously 
described
33
. 
Quantification of clusterin in plasma from REVE-2 and INCA studies 
Clusterin was quantified in plasma of REVE-2 patients by western blot. Clusterin was quantified 
in plasma of INCA patients by LC-MRM MS with SIS peptides and by ELISA (R&D systems, 
Minneapolis, MN, USA). The endogenous protein concentrations in the patient samples are 
determined through linear regression
34,35
. 
Statistical analysis 
Data summarized as medians with interquartile range (IQR) were analyzed with GraphPad 
Prism version 6.01 (GraphPad Software, San Diego, CA). Comparisons were made by Kruskal-
Wallis test for REVE-2 and INCA, Wilcoxon-Mann-Whitney test and Wilcoxon- signed rank test 
for animal and in vitro experiments, as appropriate. Correlations were carried out by Spearman 
correlation test. Results were considered statistically significant if the p<0.05. 
CIRCHF/2017/004838-R3 
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RESULTS 
Clusterin is increased in patients with high LVR following MI 
We performed differential proteomic analysis by comparing 10 pools of 5 patients from the 
REVE-2 study
9
, the pools (1 to 5) and (37-41) corresponding respectively to the lowest (- 17.0 % 
± 6.2) and the highest (+ 37.2 % ± 13) LVR (Figure 1A). Because inflammatory response and 
cytokines are particularly active in early phase after MI, we selected, for each patient pool, the 
plasma samples collected at 3 months post-MI for the differential 2D-DIGE based proteomic 
analysis.  We found 7 spots differentially expressed (P<0.05) between low and high LVR pooled 
patients. The MS analyses identified 3 spots as being clusterin (Figure 1B). Detailed 2D-spots 
corresponding to clusterin are presented for each pool of plasma analyzed (5 for no LVR and 5 
for high LVR groups) (Supplemental Figure 1, Supplemental Table 3). We observed that the 
spots 842, 853 and 873 identified as being clusterin (CLU) gathered as a cluster in this gel within 
a range of Mw (37-45 kDa) and of  pI  (4.7-5.0). 
To confirm these results, we analyzed CLU plasma levels by 1D-western blotting from 
individual plasma samples of 45 REVE-2 patients at 3 months post-MI. Patients were divided by 
tertile of ΔEDV with mean ΔEDV of -7.4% (- 13.9 to 1%) for T1, 11.0% (5.3 to 14%) for T2 and 
22.6% (18.7 to 29.5%) for T3. We observed in crude plasma one band with a molecular mass of 
36 kDa corresponding to CLU (s-CLU) that is significantly increased in plasma of patients with 
LVR (P<0.01) (Figure 1C). We also identified clusterin as being significantly increased in 
plasma from patients with LVR at 1 year post-MI (Supplemental Figure 2). 
CLU is increased in the LV of rats after MI and correlated positively with LVR 
CIRCHF/2017/004838-R3 
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To determine if increased plasma CLU levels has a cardiac origin, we analyzed CLU 
expression in the LV of rats at 7 days and 2 months post-MI. In this model, cardiac remodeling 
was characterized by LV dilatation as shown by significantly increased LV end-diastolic 
(LVEDD) and end-systolic (LVESD) diameters in the 2 months post-MI rats (Supplemental 
Table 4). Cardiac hypertrophy was also increased in post-MI: LV weight/Body weight 
(LVW)/BW) and heart weight (HW)/BW ratios were significantly increased in 2 months post-MI 
rats (Supplemental Table 4). Also, mRNA levels of ANP and BNP genes were significantly 
increased in the LV of rats at 7 days and 2 months post-MI (Supplemental Figure 3A) but only 
BNP plasma levels were significantly increased at 7 days post-MI (Supplemental Figure 3B). 
We first analyzed CLU mRNA and its intracellular protein levels in the LV of rats after MI 
(Figure 2A). Quantitative polymerase chain reaction (qPCR) analysis showed a significant 
increase of CLU mRNA levels in the LV of rat at 7 days (median [IQR]: 1.7 [1.3-2.7] vs 1 [0.8-
1.2], P =0.001) and 2 months (1.8 [1.6-2.1] vs 1.2 [1.1-1.4], P =0.010) post-MI (Figure 2A, left 
panel). Western blot analysis detected 2 bands with a molecular mass of 60 and 40 kDa 
corresponding respectively to the precursor (p-CLU) and the mature (m-CLU) forms of clusterin. 
The mature form (m-CLU) was the predominant intraventricular form suggesting that CLU 
maturation is active in the heart independently of MI (Supplemental Figure 3C). We also 
observed that p-CLU was only significantly increased at 7 days post-MI (0.05 [0.03-0.06] vs 0.03 
[0.02-0.03], P=0.037) (Figure 2A, middle panel). However, m-CLU was significantly increased 
at 7 days (0.65 [0.54-0.81] vs 0.29 [0.28-0.4], P=0.001) and 2 months post-MI (0.49 [0.37-0.58] 
vs 0.37 [0.31-0.41], P=0.035) compared to the sham-rats (Figure 2A, right panel). However, a 
significant decrease of p-CLU (0.025 [0.02-0.034] vs 0.05 [0.027-0.061], P=0.033) and m-CLU 
CIRCHF/2017/004838-R3 
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(0.5 [0.38-0.59] vs 0.65 [0.54-0.81], P=0.032) levels was observed in the LV of MI rats at 2 
months compared to 7 days post-MI (Figure 2A, middle and right panels). 
Next, we verified if increased CLU expression in the LV was associated with cardiac 
remodeling. CLU mRNA level was positively correlated with ANP and BNP expression at 7 days 
(r=0.76, P=0.002 / r=0.85, P <0.001, respectively) and 2 months post-MI (r=0.78, P <0.001/ 
r=0.67, P=0.004, respectively) (Figure 2B). Cardiac p-CLU and m-CLU levels were positively 
correlated with plasma BNP levels (r=0.69, P=0.004/ r=0.59, P=0.018, respectively) at 7 days 
post-MI (Figure 2C, left panel). The cardiac m-CLU levels were positively correlated with 
LVEDD (r=0.59, P=0.004), LVW/BW ratio (r=0.48, P=0.034) and HW/BW ratio (r=0.52, 
P=0.02; data not shown) at 2 months post-MI (Figure 2C, right panel). These data show that CLU 
expression is increased in LV after MI and is correlated with cardiac remodeling. However, CLU 
expression is time-dependent after MI, suggesting different mechanisms of CLU regulation and 
different roles of this protein in cardiac remodeling. 
Clusterin expression and secretion are increased in hypertrophied cardiomyocytes  
Chronic activation of the adrenergic system with associated up-regulation of the renin–
angiotensin–aldosterone (RAA) system plays a major role in cardiac remodeling after MI. To 
determine the implication of these mechanisms on CLU secretion, we treated H9c2 cells for 48h 
by Angiotensin II (AII, 2 µmol/L), phenylephrine (PE, 20 µmol/L) and isoproterenol (ISO, 10 
µmol/L), agonist of alpha- and beta-adrenergic receptors, respectively. Western blots analysis 
showed increased s-CLU level in the culture media of H9c2 treated cells compared to untreated 
cells with the strongest effect with ISO treatment (1.7 [1.1-1.8] vs 1, P =0.03). The increased s-
CIRCHF/2017/004838-R3 
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CLU level was confirmed at 72h after ISO treatment (2.7 [2-5.3] vs 1, P =0.02) (Supplemental 
Figure 4A). 
 To determine the implication of hypertrophy on CLU regulation, we treated primary cultures 
of neonatal rat cardiomyocytes (NCM) by ISO (10 µmol/L) for 72h, and characterized cell 
hypertrophy by increased cell surface area (Figure 3A) and significant increased expression of 
ANP and BNP genes (Figure 3B). As shown in Figure 3C, the treatment of NCM by ISO 
increased significantly CLU mRNA level (1.6 [1.1-2] vs 1 [0.9-1], P=0.01) (left panel), p-CLU 
level (1.81 [1.46-2.23] vs 0.94 [0.9-1.13], P<0.001) and m-CLU level (7.85 [6.75-10.9] vs 6.43 
[5.80-7.83], P=0.049) (middle and right panels). Western blot analysis showed increased s-CLU 
level in culture media of NCM at 72h (1.31 [1.19-1.74] vs 0.96 [0.85-1.12],  P<0.001) after ISO 
treatment compared to control cells (Figure 3D). These data confirm that CLU expression and 
secretion are increased by hypertrophied cardiomyocytes and suggest that increased CLU in 
plasma after MI has at least in part a cardiac origin. 
CLU silencing in cardiomyocytes inhibits cell hypertrophy induced by isoproterenol  
Since CLU expression and secretion were increased in hypertrophied cardiomyocytes, we 
studied its role on hypertrophy by silencing it in order to understand its involvement in cardiac 
remodeling post-MI. We verified that ISO treatment increased significantly phospho Akt 
(Ser473)/total Akt (pAkt/Akt) ratio, phospho ERK1/2 (Thr202/Tyr204)/total ERK1/2 (pERK1-
2/ERK1-2) ratio as previously described
36,37,38
 with no significant difference on pGSK-3β (Ser9)/ 
total GSK-3β (pGSK/GSK) ratio (Supplemental figure 4B). CLU silencing in hypertrophied 
H9c2 cells (Figure 4A) decreased cell size (Figure 4B) and was associated with significant 
decreased pERK1/ERK1 (0.79 [0.71-0.9] vs 1.01 [0.93-1.07], P<0.001) and pERK2/ERK2 (0.87 
CIRCHF/2017/004838-R3 
 
12 
 
[0.77-0.98] vs 1.01 [0.93-1.07], P<0.001) ratios. However, CLU silencing increased significantly 
pAkt/Akt ratio (1.31 [1.2-1.5] vs 0.97 [0.9-1.1], P =0.002) with no significant difference on 
pGSK/GSK ratio (Figure 4C). On another hand, CLU silencing in hypertrophied NCM by using 
the siRNA-Clu-1 (the first siRNA of pool used in panels A-C) decreased significantly CLU 
expression (0.24 [0.19-0.34] vs 0.8 [0.66-1], P<0.001) and CLU secretion (0.04 [0.04-0.07] vs 
1.02 [0.79-1.21], P<0.001) (Figure 4D) and decreased significantly ANP (0.63 [0.41-0.73] vs 
0.97 [0.84-1.07], P<0.001) and BNP (0.35 [0.31-0.55] vs 0.7 [0.48-0.87], P<0.001) expression 
(Figure 4E) associated with significantly decreased pERK1/ERK1 (0.74 [0.59-0.85] vs 0.95 
[0.78-1.19], P=0.004) and pERK2/ERK2 (0.56 [0.42-0.72] vs 0.98 [0.79-1.21], P<0.001) ratios 
as with the siClu-pool (Figure 4F). These results suggest that CLU silencing inhibits 
isoproterenol induced hypertrophy by inhibition of ERK1/2 pathway. 
CLU is a predictive marker of cardiac mortality in heart failure patients 
Since CLU protein levels were higher in the LV of HF rat model than in control rats, we 
sought to evaluate whether this was also the case in myocardial tissue of HF patients who 
underwent heart transplantation. We observed an increased level of p-CLU (1.34 [1.17-1.93] vs 
0.99 [0.87-1.13], P=0.009) and m-CLU (5.34 [3.83-7.9] vs 2.68 [2.27-3.28], P=0.009) in LV of 
HF patients compared to controls (Figure 5A). Using immunohistochemistry, we also observed 
an increased CLU staining in failing hearts compared to control hearts with no difference on CLU 
cellular localization (Figure 5B).  
To evaluate whether the secreted form of CLU (s-CLU) may be a predictor of adverse effects 
in HF patients before heart transplantation, we quantified, by two methods (quantitative mass 
spectrometry and ELISA), s-CLU in plasma of chronic systolic HF patients (99 alive and 99 dead 
CIRCHF/2017/004838-R3 
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patients) from the INCA study recently described
24
. The baseline characteristics of the patients 
included were matched on age, sex, HF etiology, diabetes. There was no significant difference in 
treatment at inclusion in the study. The patients who died from a cardiovascular cause during the 
3-year follow-up showed significantly higher NYHA class, BNP level, creatinine level, and lower 
peak VO2 as compared to patients alive at 3 years. Plasma CLU was increased significantly (73.6 
[58.3-82.4] x 10
3
 vs 30.3 [28.5-73] x 10
3
, P<0.001 (MS), 150 [103-185] vs 134 [99-164], P=0.03 
(ELISA) in patients with early cardiac mortality compared to survivors (Figure 5C), 
independently of HF etiology (not shown). 
CIRCHF/2017/004838-R3 
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DISCUSSION 
LVR post-MI is associated with an increased risk of HF and death
39
. It remains a frequent 
event despite the modern therapeutic approach and difficult to predict in clinical practice. For 
this, we designed the REVE-2 study which included 246 patients after a first anterior MI with 
serial echocardiography examinations and serial samplings in the first year after MI
9
. Our aim 
was to identify new biomarkers of LVR post-MI and understand their involvement in this 
evolutive process. 
The development of proteomic analysis techniques makes possible to use new strategies 
without a priori for the identification of proteins involved in cardiovascular pathologies
40
. To 
identify new biomarkers of LVR post-MI, we performed a differential proteomic analysis, by 2D-
DIGE
41
, on enriched plasma prepared as previously described
30
, obtained from REVE-2 patients 
with high LVR and patients with no LVR evaluated 1 year after an anterior inaugural MI. We 
identified several polypeptidic spots corresponding to CLU. The observed molecular mass 
differences for CLU isoforms in our proteomic study can be explained by the potential N-
glycosylation of CLU, consisting of associated complex sugars contributing to 20-30% of its 
molecular weight
42
. We validated our results by western blot analysis showing that s-CLU 
isoform with a molecular mass of ~36 kDa is positively associated with high LVR post-MI. 
CLU is constitutively expressed in most mammalian tissues and is induced in many organs 
where tissue injury or remodeling occurs. CLU levels were shown to be increased in plasma of 
patients after 24h of acute MI
17
 and recently described in the exosomes isolated from pericardial 
fluids collected from MI patients
18
. Our proteomic data is the first study showing that CLU is 
increased in late stage of MI and is associated with LVR. To verify if increased CLU levels in 
CIRCHF/2017/004838-R3 
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plasma (s-CLU) of LVR patients has in part a cardiac origin, we first used an experimental MI rat 
model
25
 in order to analyze the temporal CLU expression in the LV following MI. s-CLU is 
obtained by proteolytic cleavage of its precursor (p-CLU, 60 kDa) to generate alpha and beta 
chains of 40 kDa that are glycosylated and assembled to give the mature form, m-CLU that will 
be then secreted (s-CLU). Our results show that CLU mRNA and its intracellular levels are 
increased in non-infarcted LV area of MI rat with the mature form as being predominant, 
suggesting that LV cells are able to express and secrete CLU into the bloodstream. Our results 
also show that CLU is increased as early as 7 days after MI and correlated with LVR parameters. 
This finding suggests an implication of CLU in LVR.  
To verify if increased CLU expression in the LV is associated with increased CLU secretion, 
we induced hypertrophy in NCM, a mechanism observed in the non-infarcted area after MI. The 
72h-isoproterenol treatment increased CLU expression as shown by its mRNA and intracellular 
levels. Our results are in agreement with a previous study showing increased CLU levels in the 
LV of mouse after chronic β-adrenergic stimulation43. Interestingly, we also observed increased 
CLU in the culture media of hypertrophied NCM. All these data show that CLU expression and 
secretion are increased in hypertrophic cardiomyocytes and suggests that the increased CLU 
plasma levels in REVE 2 patients with high LVR after MI has, in part, a cardiac origin.  
The physiological role of CLU is complex depending on CLU isoforms, localization and 
cellular types
44
. Several data suggest an anti-apoptotic role of CLU in early phase after MI. In 
ischemia/reperfusion rat model, the administration of CLU for 3 days reduced both infarct size 
and death of rats
45
. In addition, infusion of CLU after acute MI reduced the cardiomyocyte 
apoptosis and increased the induction of epithelial mesenchymal transition, angiogenesis and 
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preservation of myocardial function
18
. In vitro, the addition of CLU in culture media inhibited 
H9c2 apoptosis induced by ischemic/reperfusion
46
. However, in MI rats, CLU was also detected 
in peri-infarct zone
47
. These data in addition to our results lead us to study the role of CLU on 
hypertrophy. In our model, CLU silencing in cardiomyocytes decreased cells size, ANP and BNP 
expression associated with decreased ERK1/2 activity suggesting a pro-hypertrophic role of CLU 
in LVR via ERK1/2 pathway. This is supported by previous studies showing, in one hand, a 
decrease of ERK1/2 pathways after CLU silencing in cancer cells
48
 and in another hand, a 
protective effect of some molecules against hypertrophy via inhibition of ERK1/2 activity
49
.  
Finally, we validate that CLU expression is also increased in the LV of HF patients that 
underwent heart transplantation. We evaluated whether the secreted form of CLU may be a 
predictor of adverse effects in HF patients before heart transplantation, and we showed 
significantly increased CLU levels in HF patients who died from a cardiovascular cause during 
the 3-year follow-up compared to survivors, and it is not depending on the HF etiology. 
However, a recent prognostic study showed a decreased of CLU levels in the plasma of HF 
patients who died compared to survivors
20
. The discrepancy results observed between the two 
studies can be explained by a different design of the study. In our case, we performed a case-
control study and they included consecutive older HF patients hospitalized, with only 1/3 of the 
patients with altered ejection fraction (<30% vs 100% in our study), a higher female/male ratio 
and more HF patients with NYHA class III and IV vs no class IV patients in our study. A recent 
study confirmed our data with increased levels of CLU found in circulating extracellular vesicles 
derived from dilated cardiomyopathy patients compared to controls
50
. As in our study, the 
patients were relatively young (62.3±11.5 years), mostly men (90%) with reduced ejection 
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fraction (36.1 ± 11.7) and a ratio NYHA II/III (80/20). Our results suggest that CLU is a new 
predictive marker of early cardiac mortality.  
In conclusion, our data show that CLU is increased in non-infarcted LV at late stage of MI in 
the rat model. CLU expression is time-dependent in post-MI suggesting different mechanisms of 
CLU regulation and different roles of this protein in cardiac remodeling. Our data suggest that 
CLU is involved in the compensatory hypertrophy but its role in HF is not yet elucidated. Since 
the role of CLU is complex depending on CLU isoforms, localization and cellular types, it will be 
important to study the mechanisms involved in CLU expression, maturation, secretion and 
degradation in cardiomyocytes in order to better understand its regulation and its role in different 
phase after MI.  In addition, our study is the first showing that circulating levels of CLU are 
associated with LVR post-MI and is a new predictive marker of cardiac mortality in HF patients 
with reduced EF. To consider CLU as a clinically useful biomarker, it should be validated in 
other cohorts of patients. Our results were obtained in selected patients: 1) with first anterior MI 
and substantial residual akinesia at predischarge echocardiography; they may not apply to all 
post-MI patients and; 2) relatively young HF patients with reduced EF. Finally, a gold standard 
and accurate measurement of CLU usable at hospital should be developed. 
 
WHAT IS NEW?  
 This is the first study analyzing the relationship of plasma clusterin levels with left 
ventricular remodeling following myocardial infarction, discovered by proteomic 
analysis. 
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 Our findings suggest that clusterin is involved in compensatory hypertrophy and played a 
role in early and late phase following myocardial infarction. 
 Modulation of plasma clusterin levels is in part of cardiac origin following hypertrophy of 
cardiomyocytes. 
 We show a pro-hypertrophic role of clusterin via ERK1/2 pathway in cardiomyocyte 
under beta-adrenergic stress. 
 
WHAT ARE THE CLINICAL IMPLICATIONS?  
 Despite modern therapeutic approaches, left ventricular remodeling following myocardial 
infarction remains relatively frequent and difficult to predict in clinical practice. 
 Clusterin plasma levels are associated with left ventricular remodeling development 
following myocardial infarction. 
 Our findings suggest that clusterin is involved in compensatory hypertrophy and played a 
role in early and late phase following myocardial infarction. 
 Clusterin plasma levels is new predictive marker of early cardiac mortality in heart failure 
patients with reduced ejection fraction. 
 A significant increase of intracellular clusterin was found in failing human hearts. 
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FIGURE LEGENDS 
Figure 1: Discovery of clusterin as biomarker of high LVR by differential 2D-DIGE 
proteomic analysis. A: Constitution of pooled patients according to the increasing percent of 
LVR. Five pools with the lowest (1-5) and the highest (37-41) percent of LVR were used for the 
2D-DIGE analysis after treatment of pooled plasma by the CPLL method as previously described 
30
. B: Representative 2D-DIGE gel and bioinformatic analysis of spots surrounded corresponding 
to clusterin in pooled plasma of patients with the lowest and highest percent of LVR at 3 months 
post-MI. C: Representative western blot (left panel) and quantification (right panel) of clusterin 
(s-CLU) in plasma of 45 REVE-2 patients at 3 months post-MI. Patients were divided by tertile 
of ΔEDV (n=15 per tertile), with mean ΔEDV of -7.4% (- 13.9 to 1%) for T1, 11.0% (5.3 to 
14%) for T2 and 22.6% (18.7 to 29.5%) for T3. M: size marker, S: standard added in each 1D-gel 
performed for normalization between gels. Red ponceau was used to normalize clusterin levels. 
Data are expressed in arbitrary unit (A.U.) and presented as box and whisker plots showing 
median (line) and min to max (whisker). Statistical significance was determined by Kruskal-
Wallis test. ** P<0.01. 
Figure 2: Clusterin expression is increased in the left ventricle after MI and correlated 
positively with LVR parameters. A: Analysis of clusterin expression in LV of sham and MI-
rats at 7 days and 2 months after ligation. Quantification, by RT-qPCR, of clusterin (CLU) 
mRNA levels (left panel) in the LV of sham- and MI- rats at 7 days (n=8/group) and 2 months 
(n=9/group) post-MI. HPRT was used to normalize CLU expression. Representative western 
blots and quantification of intraventricular levels of precursor (p-CLU, middle panel) and mature 
(m-CLU, right panel) forms of clusterin at 7 days (n=8/group) and 2 months (n=11/group) post-
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MI. GAPDH was used to normalize CLU levels. Data are expressed in arbitrary unit (A.U.) and 
presented as box and whisker plots showing median (line) and min to max (whisker). Statistical 
significance was determined by Wilcoxon-Mann Whitney test. *P<0.05, **P<0.01 vs Sham rats 
and 
#
P<0.05 vs 7 days. B: Correlation of CLU mRNA with ANP (atrial natriuretic  
peptide) and BNP (brain natriuretic  
peptide) mRNAs in LV of MI rats at 7 days (left panels, n=14) and 2 months post-MI (right 
panels, n=17). C. Correlation of intraventricular clusterin (p-CLU or m-CLU) with BNP plasma 
levels at 7 days post-MI (left panels, n=16), and with LV weight/ body weight ratio (LVW/BW) 
and with LV end diastolic diameter (LVEDD) at 2 months post-MI (right panels, n=21). 
Statistical significance was determined by Spearman correlation test.  
Figure 3: Clusterin expression and secretion are increased in hypertrophied 
cardiomyocytes. The isolated rat neonatal cardiomyocytes (NCM) were cultured in 1% SVF 
medium without (cont.) or with 10 µmol/L of isoproterenol (ISO) for 72 hours. A: Representative 
control- and ISO-treated cells observed by phase-contrast (upper panels) and fluorescence 
microscopy after incubation with cell Mask red plasma membrane stain (lower panels), nuclei are 
stained in blue by DAPI. B: RT-qPCR analysis of cardiac hypertrophic markers genes (ANP and 
BNP) in the ISO-treated cells (n=9) compared to control cells (n=7). GAPDH was used to 
normalize ANP and BNP expression and data are expressed in arbitary units (A.U.). C: Analysis 
of CLU expression in NCM after ISO treatment. Quantification by RT-qPCR, of CLU mRNA 
levels (left panel) in the ISO-treated cells (n=9) compared to control cells (n=7). GAPDH was 
used to normalize CLU expression and data are expressed in arbitary units (A.U.). Representative 
western blot (middle panel) and quantification (right panel) of intracellular levels of precursor (p-
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CLU) and mature (m-CLU) forms of clusterin in the ISO-treated cells (n=13) compared to 
control cells (n=13). Sarcomeric actin (S-Actin) was used to normalize intracellular CLU levels 
and  data are expressed in  fold change in CLU levels relative to p-CLU of control cells. D: 
Representative western blot (left panel) and quantification (right panel) of secreted CLU levels 
(s-CLU) in the culture media of NCM treated by ISO (n=19) compared to control cells (n=18). 
Red ponceau (RP) was used to normalize secreted CLU levels and data are expressed in fold 
change in CLU levels relative to control cells. All data are presented as box and whisker plots 
showing median (line) and min to max (whisker). Statistical significance was determined by 
Wilcoxon-Mann Whitney test and by Wilcoxon signed rank test. *P<0.05, **P<0.01, 
***P<0.001 vs control cells and 
###
P<0.001 vs p-CLU.              
Figure 4: Clusterin silencing inhibited cardiomyocytes hypertrophy induced by 
isoproterenol. The H9c2 cells and NCM were transfected by siRNA non target (si-NT) used as 
control or siRNA targeting clusterin (si-Clu pool [siRNA 1 to 4] for H9c2 cells and si–Clu 1 
[siRNA 1] for NCM) 24h before treatment by isoproterenol (ISO) for 72h. A: Representative 
western blot of s-CLU levels in the culture media of H9c2 cells after CLU silencing (si-Clu pool) 
compared to si-NT transfected cells. B: Cell mask plasma membrane staining of H9c2 cells after 
CLU silencing (si-Clu pool) compared to si-NT transfected cells treated or no by ISO. Nuclei are 
stained in blue by DAPI. C: Representative western blot (left panels) and quantification (right 
panels), of active form (phosphorylated/total ratio) of Akt, GSK-3β and ERK1/2, in the H9c2 
cells after CLU silencing (si-Clu pool) compared to si-NT transfected cells (n=12/group). Data 
are expressed in fold change in active proteins levels relative to si-NT transfected cells. D: 
Quantification by RT-qPCR of CLU mRNA (left panel) and by western blot, of s-CLU levels in 
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the culture media (right panel) of NCM after CLU silencing (si-Clu 1) compared to si-NT 
transfected cells (n=11/group). For RT-qPCR analysis, GAPDH was used to normalize CLU 
expression and the data are expressed in arbitary units (A.U.). For western blot analysis, red 
ponceau (RP) was used to normalize s-CLU levels and the data are expressed in fold change 
relative to si-NT transfected cells. E: Quantification by qPCR, of ANP (left panel) and BNP 
(right panel) expression in the NCM cells after CLU silencing (si-Clu 1) compared to si-NT 
transfected cells (n=17/group). GAPDH was used to normalize ANP and BNP expression and 
data are expressed in arbitary units (A.U.). F: Representative western blots (left panels) and 
quantification (right panels) of active form of ERK1/2 (pERK1/ERK1 and pERK2/ERK2) in the 
NCM after CLU silencing (si-Clu 1) compared to si-NT transfected cells (n=19/group). Data are 
expressed in fold change in active proteins levels relative to si-NT transfected cells. All data are 
presented as box and whisker plots showing median (line) and min to max (whisker). Statistical 
significance was determined by Wilcoxon- Mann Whitney test. *P<0.05, **P<0.01, ***P<0.001 
vs si-NT transfected cells.                               
Figure 5: Clusterin protein levels in human myocardial and plasma samples from HF 
patients.  A: Western Blot and quantification of clusterin precursor (p-CLU) and its mature form 
(m-CLU) levels in LV biopsies obtained from non-failing controls (cont.) or heart failure (HF) 
patients with ischemic dilated cardiomyopathy (n=6/group). ↑: indicate the samples used for 
immunostaining in B. GAPDH was used to normalize intracellular CLU levels. Graphs show 
individual and median fold change in CLU levels ± IQR (25%-75%) relative to p-CLU of 
control. B: Immunostaining of CLU in frozen myocardial sections from non-failing (control) and 
heart failure (HF) patients with ischemic cardiomyopathy. Nuclei are stained in blue by 
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hematoxylin. C: Quantification of s-CLU plasma levels in systolic HF patients alive (n=99) or 
dead (n=99) within 3 years after the initial prognostic evaluation by quantitative mass 
spectrometry (left panel) and ELISA (right panel). Data are presented as box and whisker plots 
showing median (line) and min to max (whisker). Statistical significance was determined by 
Wilcoxon-Mann Whitney test or and by Wilcoxon signed rank test. **P<0.01 vs Cont., 
#
P<0.05 
vs p-CLU (A), *P<0.05, ***P<0.001 vs alive patients (C). 
 
 





CIRCHF/2017/004838-R2 
 
 
SUPPLEMENTAL DATA 
Expression and implication of clusterin in left ventricular remodeling after myocardial 
infarction  
 
Annie Turkieh, PhDa, Marie Fertin, MD, PhDa, Marion Bouvet, PhDa, Paul MulderPhDb, Hervé 
Drobecq, MSCc, Gilles Lemesle, MD, PhDa,d,e,f, Nicolas Lamblin, MD, PhDa,d,e,f, Pascal de 
Groote, MD, PhDa,d, Sina Porouchani, MSCa, Maggy Chwastyniak, MSCa, Olivia Beseme, 
MSCa, Philippe Amouyel, MD, PhDa,e,g, Frédéric Mouquet, MD, PhDd, Jean-Luc Balligand, MD, 
PhDh, Vincent Richard, PhDb, Christophe Bauters, MDa,d,e,f, Florence Pinet, PhDa 
CIRCHF/2017/004838-R2 
 
 
EXPANDED MATERIALS AND METHODS 
Patients 
The studies were approved by the Ethics Committee of the “Centre Hospitalier et Universitaire de 
Lille” and comply with the Declaration of Helsinski. All patients gave written informed consent. 
REVE-2 study 
The design of the REVE-2 study has been published in detail elsewhere1. We enrolled 246 
patients with a first anterior wall Q-wave MI between February 2006 and September 2008. 
Inclusion criteria were hospitalization within 24 hours after symptom onset and at least 3 akinetic 
LV segments in the infarct zone at the predischarge echocardiography. The protocol required 
serial echographic studies at baseline (day 3 to day 7) and 3 and 12 months after MI. Serial blood 
samples were taken at baseline (day 3 to day 7), and 1, 3, and 12 months after MI. 
A standard echographic imaging protocol was used based on apical 4- and 2-chamber views. 
All echocardiograms were analyzed at the Lille Core Echo Laboratory (Lille, France), as 
previously described1. LV end-diastolic volume (EDV), LV end-systolic volume (ESV), and LV 
ejection fraction (EF) were calculated with a modified Simpson’s rule. Left ventricular 
remodeling (LVR) was defined as percent change in EDV from baseline to 1 year. 
Blood samples were collected in EDTA-containing tubes. Plasma was obtained by 
centrifugation at 800g for 10 min. Samples were aliquot, and stored at −80 °C until further 
analysis. 
INCA study  
All patients referred for evaluation of systolic HF (LVEF <45%) in our institution between 
November 1998 and May 2010 were included in a prospective cohort on prognostic indicators 
2,3,4,5
. All patients were ambulatory and clinically stable for at least 2 months, and received 
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optimal medical therapy with maximal tolerated doses of angiotensin-converting enzyme 
inhibitors and betablockers. At inclusion, patients underwent a prognostic evaluation including: 
BNP level assessment, echocardiography, and cardiopulmonary exercise testing as previously 
described2,4. In addition, patients underwent a coronary angiogram to help define the etiology of 
left ventricular (LV) systolic dysfunction as either ischemic or nonischemic. A follow-up was 
performed at 3 years to assess clinical outcome. All events were adjudicated by two investigators 
and by a third one in case of disagreement. Cardiovascular death included cardiovascular-related 
death, urgent transplantations defined as United Network for Organ Sharing (UNOS) status 1), 
and urgent assist device implantation. 
From this population, we selected 198 patients included between November 1998 and 
December 2005. Ninety nine patients who died from cardiovascular cause within 3 years after the 
initial prognostic evaluation (cases) were individually matched for age, sex, and HF etiology with 
99 patients who were still alive at 3 years (controls) as previously described6. 
At inclusion, peripheral blood was collected in tubes containing EDTA and plasma samples 
were stored at -80°C.  
Human heart biopsies  
Tissues from failing and non-failing human hearts were obtained respectively from Lille 
University Hospital (France) and from Catholic University of Leuven (Belgium). Explanted heart 
tissues were obtained from patients undergoing heart transplantation for end-stage ischemic heart 
failure and from patients died of non-cardiac causes. Samples were quick-frozen and stored at -
80°C. All materials from patients and controls were recovered as surgical waste with informed 
consent of the donors and with approval of the local ethical boards and according to the 
Declaration of Helsinki.  
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Animal models 
All animal experiments were performed according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH publication NO1-
OD-4-2-139, revised in 2011). Animals were used and experimental protocols performed under 
the supervision of a person authorized to perform experiments on live animals (F. Pinet: 59-
350126). Approval was granted by the institutional ethics review board (CEEA Nord Pas-de-
Calais N°242011, January 2012).  
Before surgery, rats were anaesthetized (sodium methohexital, 50 mg/kg intraperitoneally 
(IP)), while analgesia was administered before (xylazine 5 mg/kg IP) and 1 hr after surgery 
(xylazine 50 mg/kg subcutaneously) as described 7. Anesthesia and sedation were controlled by 
monitoring heart rate. MI was induced in 10-week-old male Wistar rats (Janvier, Le Genest St 
isle, France) by ligation of the left anterior descending coronary artery7,8. Sham-operated and MI 
rats were then further separated in two subgroups that were sacrificed at 7 days (n=8/group) or 2 
months (n= 9 to 11/ group) post-MI. Haemodynamic and echocardiographic measurements were 
taken 2 months after surgery, followed by heart excision, as previously described9,10. 
Cellular models 
H9C2 cells 
Rat cardiac myoblasts (H9c2 cells, CRL-14146, ATCC) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM Glutamax, 31966, Gibco, Life Technologies) with addition of 10% 
(v/v) fetal bovine serum (FBS, 30-2020, ATCC) and 1% penicillin and streptomycin (P/S, 10,000 
U/mL) (15140-122, Invitrogen™, Life Technologies). Cells were cultured at 37°C under 5% CO2 
atmosphere. 
Primary cultures of neonate rat cardiomyocytes  (NCM) 
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Primary cultures of rat neonatal contractile cardiac myocytes (NCMs) were prepared from 
heart ventricles of 1- or 2-day-old rats, killed by decapitation, minced in a balanced salt solution 
containing 20 mmol/L HEPES, 120 mmol/L NaCl, 1 mmol/L NaH2PO4, 5.5 mmol/L glucose, 5.4 
mmol/L KCl, and 0.8 mmol/L MgSO4 [pH 7.4] and then digested by using pancreatin and 
collagenase type II as previously described11. NCMs were purified by centrifugation of the cells 
at 2800 rpm for 30 min on Percoll gradients (58.5% and 40.5% in the balanced salt solution). 
NCMs were seeded at a density 6.5 × 105 cells/well in 6-well plates coated with 10% of collagen 
(Sigma-Aldrich) and cultured in a medium containing 4 parts of Dulbecco’s modified Eagle’s 
medium (DMEM, D1152, Sigma-Aldrcih) and 1 part of Medium199 (M199, M2520, Sigma), 
10% FBS and 1% P/S  at 37°C under 5% CO2 atmosphere. 
Hypertrophic treatment  
After 24h of seeding, cells were serum deprived for 24 h and then treated  with isoproterenol 
(10 µmol/L, Tocris Bioscience, 1747), Angiotensin II (2 µmol/L,  A9525, Sigma-Aldrich) or 
phenylephrine (20 µmol/L, 2838, Tocris Bioscience) for 48 h or 72h in the presence of 1% FBS. 
Transfection studies 
To inhibit the expression of Clusterin, cells were transfected by 25 nmol/L of siRNA non 
target (D-001810-10-20, Dharmacon) as a control or ON-TARGETplus Rat Clu siRNA  (Smart 
pool, or the first individual siRNA, Dharmacon) using Darmaphect according to the 
manufacturer’s instructions. For treatment of transfected cells with isoproterenol, the transfection 
was occurred in serum and P/S free medium 24h before the treatment. 
Immunostaining studies 
Immunohistochemistry  
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Frozen human heart tissues were included in Richard-Allan Scientific Neg-50TM 
(ThermoFisher Scientific). Tissue Sections (5 µm thickness) were fixed with acetone/methanol 
(V:V) for 20 min at -20°C. The endogenous peroxidase activity was blocked in 0.3% hydrogen 
peroxide (H2O2) in methanol for 30 min at room temperature. After washing with TN (Tris 2.42 
g/L and NaCl 29.22 g/L in water), the sections were saturated with TNO (TN with ovalbumin at 5 
g/L) for 30 min at room temperature and then incubated with polyclonal rabbit clusterin antibody 
(ab42673, Abcam) diluted at 1/50 in TNO overnight at 4°C. After washing with TNO, Sections 
were incubated with anti-rabbit biotinylated secondary antibody (BA-1000, Vector laboratories) 
diluted at 1/200 in TNO for 1h at room temperature, washed and then incubated in Vectastain 
Elite ABC Kit (vector laboratories) for 30 min. Finally the sections were developed in ABC 
staining kit (sigma) for 5 min, counter-stained with hematoxylin to identify nuclei and mounted 
in glycerol. Staining was visualized with the x20 and x40 objectives of color Axioplan 2 
microscope followed by Zen image acquisition. 
Immunofluorescence 
For measuring cell surface area, the cells were plated at a density of 2 x 105 cells on coverslip 
(24 mm x 24 mm) for H9c2 cells and 8x108 cells on coverslip coated with collagen for NCM in a 
6-wells culture plate. After treatment, the cells were incubated with the complete medium 
containing Hoechst (33342, Invitrogen) for 30 min at 37°C to color nuclei, then with the Cell 
Mask plasma membrane stain (C10046, Life Technology) at a final concentration of 1X in the 
medium for 10 min at 37°C. The cells were then fixed with 3.75 % paraformaldehyde (43368, 
Thermofisher) for 10 min at room temperature and then wash three times for 5 min with PBS 1X. 
The coverslips were mounted on slides with glycerol 90%. Staining was visualized with the x40 
objectives of LSM710 confocal microscope followed by Zen image acquisition.  
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Proteomic analysis of plasma samples from REVE-2 patients 
Constitution of pooled plasma samples 
The follow-up of REVE-2 study was completed for 205/246 patients (serial echography and 
blood samples). The 205 patients were ranked by the increasing percentage of LVR, and then 
grouped together by 5, defining 41 pools. The pools with the lowest (1 to 5) and with the highest 
(37-41) percent of LVR were constituted by mixing an equal volume of plasma from the 5 
patients in the same group (Figure 1A). 
Processing of pooled plasma 
Prior to the proteomic study, plasma samples underwent no more than two freeze/thaw cycles. 
One mL of each plasma sample was treated with the ProteoMiner™ kit (Bio-Rad Laboratories, 
Hercules, CA, USA) as previously described12,13. This combinatorial peptide ligand library 
(CPLL) method has been shown to be reproducible and to allow for the enrichment in medium- 
and low-abundance proteins14. Samples were eluted by adding 100 µL elution reagent, repeated 
three times and the pooled samples were  stored at −20°C, before the protein concentration was 
determined  for 2D analysis.  
2D-DIGE electrophoresis  
Two gels (technical replicates) of each sample were run with a total of 10 µg of mixed labelled 
protein per gel. These protein mixtures contained 5 µg of protein from each REVE 2 sample 
group (pool of 4 patients and pool of 4 healthy donors) randomly labelled with 400 pmol 
saturation CyDye DIGE fluors (Cy3 or Cy5) and 50 µg of the two pools mix (25 µg from patients' 
pool and 25 µg from healthy donors' pool) labeled with 400 pmol Cy2. Five micrograms of each 
sample were reduced with 2 mM Tris (2-carboxyethyl)phosphine (TCEP) for 1 h at 37 °C. 
Cyanine 3 (Cy3) and cyanine 5 (Cy5) sulfhydryl-reactive dyes (0.8 nmol/µg protein) were added 
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respectively to REVE2 and standard samples and incubated for 30 min at 37 °C in the dark. The 
reaction was stopped with the addition of an equal volume of sample buffer containing 7 mol/L 
urea, 2 mol/L thiourea, 4% CHAPS, 130 mmol/L dithiothreitol (DTT) and, 2% pharmalytes (GE 
Healthcare).The Cy3-labelled REVE samples were then mixed with Cy5-labelled standard 
samples and left for 15 min on ice in the dark. Immobilized pH gradient (IPG) strip (240 mm, pH 
4–7 linear gradient) was rehydrated with 450 µl of labelled mixed samples in rehydration buffer 
containing 1% Pharmalytes, 1300 mmol/L DTT, 7 mol/L urea, 2 mol/L thiourea and 4% CHAPS 
on a Protean IEF cell system (Biorad) for 24 h without applying any current. After rehydration, 
IEF was performed at 300 volts (V) for 3 h, and then at a gradient to 1000 V for 6 h, at a gradient 
to 8000 V for 3 h and finally at 8000 V for 3 h with the temperature maintained at 20 °C. After 
IEF, the IPG strips were  incubated in equilibration buffer containing  6 mol/L urea, 0.1 mmol/L 
Tris-HCl pH 8, 2% w/v sodium dodecyl sulfate (SDS) and 30% v/v glycerol for 10 min at room 
temperature. The equilibrated IPG strips were transferred for the second dimension (SDS-
polyacrylamide gel electrophoresis (PAGE)) onto 12% PAGE gels and seal with low-melting 
agarose. Electrophoresis was carried out at 20 °C using an Ettan Dalt 6 system (GE Healthcare) 
at a constant voltage of 70 V overnight followed by 300 V in the dark. 
Following electrophoresis, gels were scanned with an Ettan DIGE Imager (GE Healthcare) at 
excitation/emission wavelengths of 532/580 nm for Cy3 and 633/670 nm for Cy5 to yield images 
with a pixel size of 100 µm. Gel images were processed with Progenesis SameSpots (v 3.0) from 
Nonlinear Dynamics Ltd. (Newcastle, UK) as previously described15. First, the images were 
classified by pairs which corresponded to comigration of one standard and one REVE2 sample in 
the same gel. After choosing the image of reference, the whole 2D-images were automatically 
aligned in 2 steps (all the standards’ images were aligned then each REVE2 sample’s image is 
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aligned with the image of comigrating standard). All gels were compared with the reference gel 
to normalize spots’values. An average of 429 spots per gel was detected. Each spot was 
normalized by the ratio between intensities of Cy3-REVE-2 sample and Cy5-standard. We then 
compared the normalized spots (Cy3-REVE-2/Cy5-standard). Fold values as well as p-values of 
all spots were calculated by SamesSpots software using one way ANOVA analysis. Differential 
expression of a protein present in the gels was considered significant when the p value was below 
0.05 (one-way ANOVA analysis). 
Differentially regulated spots were excised manually from a preparative gel performed with 
500 µg of proteins and in-gel digested with trypsin16. Identifications were performed by MALDI-
TOF with a Voyager DE STR mass spectrometer (PerSeptive Biosystems, Framingham, MA, 
USA) equipped with a 337.1 nm nitrogen laser and a delayed extraction facility (125 msec). All 
spectra were acquired in a positive ion reflector mode under 20 kV voltage, 61% grid. The mass 
spectra were then calibrated before protein identification by peptide mass fingerprinting, 
conducted by running the MASCOT web searcher (http://www.matrixscience.com, Matrix 
Science, UK) against the NCBInr 20080718 (6833826 sequences; 2363426297 residues) with the 
following parameters: Fixed modifications: CyDye-Cy3 (C); Variable modifications: Oxidation 
(M); Peptide Mass Tolerance: ± 50 ppm; Peptide Charge State: 1+; Max Missed Cleavages: 1 as 
previously described15. Some spots were identified with nano-LC- MS/MS (on an UltraflexTM 
TOF/TOF instrument).  
RNA extraction and quantitative real time-polymerase chain reaction (qRT-PCR) 
RNA was extracted from LV with TRI Reagent (Ambion, Austin, TX, USA) and from NCM 
with QIAGEN RNeasy Mini Kit (Qiagen), as described by the manufacturers’s instructions.  
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Then, 500 ng of LV RNA and 250 ng of NCM RNA were reverse-transcribed using the 
miScript II RT kit (Qiagen). qRT-PCR was performed with the miScript SYBR Green PCR kit 
(Qiagen) on a Mx3005P Q-PCR system (Agilent Technologies), according to the manufacturer’s 
instructions. The sequences of the different primers (Eurogentec) used were: rat ANP (sense: 
CCGGTACCGAAGATAACAGC and antisense: CTCCAGGAGGGTATTCACCA), rat BNP 
(sense:CTGGGAAGTCCTAGCCAGTCTCCA and antisense: 
GCGACTGACTGCGCCGATCCGGTC), rat Clu (sense: GCTCCATAGCCCAGCTTTAC and 
antisense: ACTTCTCACACTGGCCCTTC), rat GAPDH (sense: 
GGCATTGCTCTCATTGACAA and antisense: TGTGAGGGAGATGCTCAGTG), and rat 
HPRT (sense: ATGGGAGGCCATCACATTGT and antisense: 
ATGTAATCCAGCAGGTCAGCAA-. ∆∆CT method was used for data analysis. 
Western blot analysis 
Antibodies 
The primary antibodies used for western blot analysis were: Clusterin (sc-6419) and GAPDH 
(sc-365062) antibodies from Santa Cruz Biotechnology; Clusterin (RD182034110) from 
Biovendor; phospho-Akt (Ser473) (9271), phospho-GSK-3β (Ser9)(9336), phospho-ERK1/2 
(Thr202/Tyr204) (4376), Akt (9272), GSK-3β (9315), and ERK1/2 (9102) antibodies from Cell 
signaling and Sarcomeric-actin (m0874) antibody from Dako. The horseradish peroxidase-
labelled secondary antibodies used were: anti-rabbit IgG (NA934V) and anti-mouse IgG 
(NA931) antibodies from GE healthcare and anti-goat IgG antibody (sc-2020) from Santa Cruz 
Biotechnology. The dilution of antibodies used for Western blot depended of each sample (see 
details in the Supplemental Table 1).   
Protein extraction 
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H9c2 and NCM protein extracts were collected by scraping cells into ice-cold RIPA buffer (50 
mmol/L Tris pH 7,4, 150 mmol/L NaCl, 1% Igepal (Sigma, CA-630), 50 mmol/L sodium 
deoxycholate, and 0.1% SDS) containing anti-proteases (Roche, 11836145001/ 1 tablet for 50 
mL of buffer), 1 mmol/L sodium orthovanadate (Sigma, S6508) and 1% protein phosphatase 
inhibitors cocktail 2 and 3 (Sigma, P5726 and P0044). LV extracts were collected by Dounce-
Potter homogenisation on ice in RIPA buffer as described above. All extracts were then incubated 
one h at 4°C and then centrifuged at 11000 rpm, 4°C, for 10 min to remove cellular debris. The 
samples were kept at -80°C. 
Proteins from culture medium (2 mL) were precipitated with 8 mL acetone at -20°C overnight 
and then centrifuged at 2700 g, 4°C, for 15 min. The pellet was then washed 3 times with 3 mL 
of cold ethanol and a centrifugation at 2700 g, 4°C, for 10 min is performed after each wash. The 
protein pellets were then dried and resuspended in 300 µL of RIPA buffer and the samples were 
stored at -80°C. 
Protein concentrations were determined with a Bradford-based method protein assay (Biorad, 
500-0006). 
Western blot 
Proteins (20 µg of NCM, 40 µg of culture media protein, 50 µg of LV protein and 1µl of 
plasma) were separated on 10% SDS-PAGE and transferred on 0.22 µm nitrocellulose 
membranes (Trans-Blot® TurboTM Transfert Pack, Bio-rad). Equal total proteins loads were 
confirmed by Ponceau red [0.1% Ponceau red, 5% acetic acid (v/v) (Sigma-Aldrich)] staining of 
the membranes. After blocking with 5% non-fat dry milk in TBS-Tween 0.1% buffer for 1 h at 
room temperature, the membranes were incubated with  primary antibodies at 4°C with gentle 
shaking overnight as described in supplemental table 1. The membranes were then washed three 
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times for 10 min with TBS-Tween 0.1% buffer and incubated with the corresponding horseradish 
peroxidase-labelled secondary antibody for 1h in the blocking solution (see details in the 
Supplemental table 1). After three washes with TBS-Tween 0.1% buffer, the membranes were 
incubated with enhanced chemiluminescence (ECL™) western blotting detection reagents (GE 
Healthcare) according to the manufacturer’s instructions.  
The Chemidoc® camera (Biorad) was then used for imaging the membranes and densitometric 
measurements of the bands were analysed with the Image Lab software (Bio-Rad). 
Quantification by multiplex immunoassay  
B-type natriuretic peptide (BNP) was measured in plasma samples using a Multi Analyte 
Profiling Kit for simultaneous quantitative detection of rat cardiovascular biomarkers (Rat CVD1 
Panel 1, RCVD1-89K Millipore) according to the manufacturer’s instructions as previously 
described 17. 
Quantification of clusterin in plasma from REVE-2 and INCA studies 
Western blot 
Western blot detection of clusterin in plasma of REVE-2 patients was performed with the 
mouse primary antibody (Hs-3, Biovendor) (1/2000).  Briefly, 1 µL of crude plasma proteins was 
resolved on 12% SDS-PAGE (NuPAGE 10% Bis-Tris gel, Life Technologies), transferred as 
described above before incubation with horseradish peroxidase-labelled secondary antibody 
(1/5000) for 1 h in blocking solution. 
ELISA 
Clusterin in plasma of INCA patients was quantified by ELISA (R&D systems, Minneapolis, 
MN, USA). The sensitivity was 0.189 ng/mL and the variability between plates estimated 
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between 3.4-3.7%.by ELISA (R&D systems, Minneapolis, MN, USA). The sensitivity was 0.189 
ng/mL and the variability between plates estimated between 3.4-3.7%. 
LC-MRM MS with SIS peptides  
The peptides had been previously validated for its use in LC-MRM experiments following the 
CPTAC guidelines for assay development (https://assays.cancer.gov). The tryptic peptide was 
selected to serve as molecular surrogate for clusterin according to a series of peptide selection 
rules (e.g., sequence unique, devoid of oxidizable residues; see 18 for detailed criteria) and 
previous detectability in pooled plasma samples. To help compensate for matrix-induced 
suppression or variability in LC-MS performance, 13C/15N-labeled peptide analogues were used 
as internal standards. The peptides (light and SIS) were synthesized via Fmoc chemistry, purified 
through RP-HPLC with subsequent assessment by MALDI-TOF-MS, and characterized via 
amino acid analysis, (AAA), and capillary zone electrophoresis (CZE) with an average CZE-
derived purity of 92.4%. 
The plasma proteolytic digests were prepared in an automated manner on a Tecan Freedom 
EVO 150 on a 96-well microplate (Axygen). In the sample preparation, 10 µL of raw plasma was 
subjected to 9 M urea, 20 mM dithiothreitol, and 0.5 M iodoacetamide (all in Tris buffer at pH 
8.0). Denaturation and reduction occurred simultaneously at 37°C for 30 min; with alkylation 
occurring thereafter in the dark at room temperature for 30 min. Proteolysis was initiated by the 
addition of TPCK-treated trypsin (35 µL at 1 mg/mL; Worthington) at a 20:1 substrate: enzyme 
ratio. After overnight incubation at 37°C, proteolysis was quenched with 1% FA. The SIS peptide 
mixture was then spiked into the digested samples, the standard curve samples, and the QC 
samples and concentrated by solid phase extraction (SPE) (Oasis HLB, 2 mg sorbent; Waters). 
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After SPE, the concentrated eluate was frozen, lyophilized to dryness, and rehydrated in 0.1% FA 
(final concentration: 0.5 µg/µL digest) for LC-MRM/MS. 
 The standard curve was prepared using a mix of light peptides that was spiked into a human 
plasma tryptic digest in which the peptides were dimethylated (to shift their masses) from a high 
concentration of 1000X the Lower limit of quantitation (LLOQ) over 8 dilutions to the lowest 
point of the curve which was the LLOQ for the assay. The QC samples were prepared from the 
same light peptide mix and diluted in dimethylated human plasma digest at 4X, 50X, and 500X 
the LLOQ for each peptide. 
Twenty microliters injections of the plasma tryptic digests were separated with a Zorbax 
Eclipse Plus RP-UHPLC column (2.1 x 150 mm, 1.8 µm particle diameter; Agilent) that was 
contained within a 1290 Infinity system (Agilent). Peptide separations were achieved at 0.4 
mL/min over a 60 min run, via a multi-step LC gradient (2-80% mobile phase B; mobile phase 
compositions: A was 0.1% FA in H2O while B was 0.1% FA in ACN). The column was 
maintained at 40˚C.  A post-gradient equilibration of 4 min was used after each sample analysis.   
The LC system was interfaced to a triple quadrupole mass spectrometer (Agilent 6490) via a 
standard-flow ESI source, operated in the positive ion mode. The general MRM acquisition 
parameters employed were as follows: 3.5 kV capillary voltage, 300 V nozzle voltage, 11 L/min 
sheath gas flow at a temperature of 250°C, 15 L/min drying gas flow at a temperature of 150°C, 
30 psi nebulizer gas pressure, 380 V fragmentor voltage, 5 V cell accelerator potential, and unit 
mass resolution in the first and third quadrupole mass analysers. The high energy dynode (HED) 
multiplier was set to -20 kV for improved ion detection efficiency and signal-to-noise ratios. 
Specific LC-MS acquisition parameters were employed for optimal peptide 
ionization/fragmentation and scheduled MRM (see supplemental Table 2) for the dynamic MRM 
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method. Note that the peptide optimizations were empirically optimized previously by direct 
infusion of the purified SIS peptides. In the quantitative analysis, the targets (with 3 
transitions/peptide form) were monitored over 500 ms cycles and 1 min detection windows. 
The MRM data was visualized and examined with MassHunter Quantitative Analysis software 
(version B.07.00; Agilent).  This involved peak inspection to ensure accurate selection, 
integration, and uniformity (in terms of peak shape and retention time) of the SIS and NAT 
peptide forms. Thereafter, the processed response (i.e., peak area) data was inputted into our in-
house developed software tool – Qualis-SIS – for quantitative analysis. After defining a small 
number of criteria (i.e., 1/x2 regression weighting, <20% deviation in a given level’s precision 
and accuracy) for each concentration level of the standard curve, the tool automatically generates 
and extracts assay-related information from each standard curve. The endogenous protein 
concentrations in the patient samples are determined through linear regression 19,20. 
Statistical analysis 
Data summarized as medians with interquartile range (IQR) were analyzed with GraphPad 
Prism version 6.01 (GraphPad Software, San Diego, CA). Comparisons were made by Kruskal-
Wallis test for REVE-2 and INCA, Wilcoxon-Mann-Whitney test and Wilcoxon- signed rank test 
for animal and in vitro experiments, as appropriate. Correlations were carried out by Spearman 
correlation test. Results were considered statistically significant if the p<0.05. 
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Supplemental Table 1: List and dilution of antibodies used for western blot analysis 
Primary antibodies Reference Incubation buffer Sample :Dilution Secondary 
antibodies 
Dilution 
Clusterin 
 
sc-6419, Santa Cruz TBST-0.1% + 5% 
Milk 
H9c2 : 1/500  Anti-goat antibody 
(sc-2020, Santa 
Cruz) 
1/10000 
NCM Media : 1/2000  1/10000  
NCM Lysate : 1/500  1/10000  
Rat LV : 1/1000  1/5000 
Human cardiac biopsies : 
1/20000  
1/40000  
Clusterin 
 
RD182034110, 
Biovendor 
Human plasma : 1/2000 Anti-mouse antibody 
(NA931, GE 
Healthcare) 
1/5000 
pAkt (Ser473)  9271, Cell Signalling TBST-0.1% + 5% 
BSA 
1/500  Anti-rabbit antibody 
(NA934V, GE 
1/5000 
Akt   9272, Cell Signalling 1/2000 1/5000 
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pERK1/2 
(Thr202/Tyr204)  
4376, Cell Signalling 1/500 Healthcare) 1/5000 
ERK1/2  9102, Cell Signalling 1/5000 1/5000 
pGSK (Ser9)  9336, Cell Signalling 1/3000 1/10000 
GSK  9315, Cell Signalling 1/5000 1/10000 
S-Actin  mo74, Dako TBST-0.1% + 5% 
Milk 
 
1/5000  Anti-mouse antibody 
(NA931, GE 
Healthcare) 
1/10000  
GAPDH  
 
sc-36506, Santa Cruz Rat LV : 1/5000  1/10000  
Human cardiac biopsies : 
1/10000  
1/20000  
TBST : Tris Buffered Saline Tween 
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Supplemental Table 2.  Specific acquisition parameters for the target peptides for clusterin 
(P10909) measured by bottom-up LC-MRM/MS.   
Compound 
Name 
Compound  
Group 
Ion 
NAT SIS 
RT 
(min) 
CE 
(V) 
Q1 
m/z 
Q3 
m/z 
Q1 
m/z 
Q3 
m/z 
Clusterin ELDESLQVAER y3.heavy 644.83 602.33 649.83 385.21 21 12.65 
Clusterin ELDESLQVAER Y5.heavy 644.83 1046.52 649.83 612.33 21 12.65 
Clusterin ELDESLQVAER Y9.heavy 644.83 375.21 649.83 1056.52 25 12.65 
Clusterin EPQDTYHYLPFSLPHR y12+++.heavy 500.75 549.28 503.25 514.27 9 21.76 
Clusterin EPQDTYHYLPFSLPHR y13+++.heavy 500.75 409.23 503.25 552.61 9 21.76 
Clusterin EPQDTYHYLPFSLPHR y3.heavy 500.75 510.93 503.25 419.24 17 21.76 
Clusterin TLLSNLEEAK b2.heavy 559.31 790.39 563.32 215.14 17 19.65 
Clusterin TLLSNLEEAK y7.heavy 559.31 903.48 563.32 798.41 17 19.65 
Clusterin TLLSNLEEAK y8.heavy 559.31 215.14 563.32 911.49 17 19.65 
The fragmentation and cell acceleration voltages were 380 and 5 V, respectively, for all 
transitions. 
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Supplemental Table 3 : Identification by MALDI-MS of the 2D spots selected in Figure 1. 
Spot 
number* 
Accession 
number 
Protein 
name 
Mr (Da) 
Theo              Exp 
pI 
Theo              Exp 
MASCOT 
score 
Number of 
matched 
peptides/total 
peptides 
Sequence 
coverage 
(%) 
Peptides 
Mr (Exp) 
842 
853 
873 
P10909 Clusterin 
59184 
 
40000 
5.89 
4.75 65 6 / 24 12 1887.8214 
1903.8205 
1392.6909 
1074.5735 
949.4149 
1872.9244 
*Number corresponds to the spots visualized in Figure 1B 
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Supplemental Table 4: Histomorphometric and echocardiographic parameters of rats at 7 days 
and 2 months post-MI. 
 7 days post-MI 2 months post-MI 
 Sham MI Sham MI 
Number  8 8 11 11 
BW (g) 338 [311-340] 313 [294-327] 450 [437-466] 447 [415-472] 
HW (g) 0.97 [0.90-1.02] 1,04 [1.02-1.1]* 1.35 [1.29-1.43] 1.67 [1.57-1.76]*** 
LVW (g) 0.73 [0.65-0.75] 0.73 [0.67-0.76] 1.01 [0.97-1.04] 1.25 [1.2-1.3]** 
(HW/ BW) *103 2.9 [2.8-3.2] 3.3 [3.1-3.7]* 3 [2.8-3.2] 3.6 [3.3-4.3]** 
(LVW/BW) *103 2.2 [2-2.3] 2.3± [2.3-2.4]* 2.2 [2.1-2.4] 2.7 [2.4-3.3]** 
LVEDD (mm)   6.6 [6.1-7.1]  10.3 [9.3-11.5]*** 
LVESD (mm)   3.3 [2.9-4.2] 8.7 [7.4-10]*** 
FS (%)   49 [40-52] 14 [11-20]*** 
HR (bpm)   439 [396-467] 420 [377-463] 
SV (ml)   0.38 [0.38-0.47] 0.34 [0.25-0.37] 
CO (ml/min)   169 [132-195] 137 [104-166] 
 
MI: myocardial infarction, BW: body weight, HW: heart weight, LVW: left ventricle weight, 
LVEDD : left ventricle end-diastolic diameter, LVESD : left ventricle end-systolic diameter, 
FS : fractional shortening, HR : Heart rate, SV: stroke volume, CO : cardiac output. Data are 
expressed as median with 25th and 75th percentiles and statistical significance was determined by 
Wilcoxon- Mann Whitney. *P<0.05, **P<0.01, ***P<0.001 vs sham rats of the same group.  
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FIGURE LEGENDS 
Supp. Figure 1: Detailed 2D-spots and mass spectra corresponding to clusterin spots in 2D 
gels. Enlarged corresponding 2D-spot in plasma sample analyzed for each conditions, high LVR 
(n=5) and no LVR (n=5). The corresponding spot quantified by Progenesis SameSpots is circled 
for each sample.  
Supp. Figure 2: Clusterin analysis in plasma of REVE-2 patients at 1 year post-MI. A: 
Representative 2D-DIGE gel and bioinformatic analysis of spots surrounded corresponding to 
clusterin in pooled plasma of patients with the lowest and highest percent of LVR at 1 year post-
MI. The spot 1031 corresponded to spots 842 and 853 observed in 3 months post-MI. B: 
Quantification by ELISA of clusterin in plasma of 45 REVE-2 patients at 1 year post-MI. 
Patients were divided by EDV calculated at 1 year with low EDV (<56 mm2, n=22) and high 
EDV (56 mm2, n=23). Data are expressed µg/mL and presented as box and whisker plots 
showing median (line) and min to max (whisker). Statistical significance was determined by 
Wilcoxon-Mann Whitney test.*P<0.05 vs low EDV. 
Supp. Figure 3:  Quantification of cardiac hypertrophic markers and clusterin in sham- 
and MI-rats. A: Quantification by qPCR, of ANP (left panel) and BNP (right panel) expression 
in the LV of sham- and MI-rats at 7 days (n=8/group) and 2 months (n=9/group) post-MI. HPRT 
was used to normalize ANP and BNP expression and data are expressed in arbitary units (A.U.). 
B: Quantification by multiplex immunoassay of BNP levels in the plasma of sham- and MI-rats at 
7 days (n=8/group) and 2 months (n=11/group). Data are expressed in pg/ml. Data in (A) and (B) 
are presented as box and whisker plots showing median (line) and min to max (whisker) and 
statistical significance was determined by Wilcoxon- Mann Whitney test. *P<0.05, **P<0.01, 
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***P<0.001 vs sham rats. C: Quantification by western blot of levels of clusterin precursor (p-
CLU) and mature (m-CLU) forms in LV of sham- and MI-rats at 7 days (n=8/group) and 2 
months (n=11/group) post-MI. GAPDH was used to normalize CLU levels. Data are expressed in 
fold change in CLU levels relative to Sham p-CLU at 7 days (left panel) and 2 months (right 
panel) and presented as box and whisker plots showing median (line) and min to max (whisker). 
Statistical significance was determined by Wilcoxon-Mann Whitney test. ** P<0.01, *** 
P<0.001 vs p-CLU. 
Supp. Figure 4:  Effect of adrenergic and angiotensin stimulation on clusterin secretion and 
signaling pathways in H9c2 cells. A: Representative western blot (left panel) and quantification 
(right panel) of secreted clusterin levels (s-CLU) in culture media of H9c2 cells untreated (cont.) 
or treated by phenylephrine (PE, 20 µmol/L), isoproterenol (ISO, 10 µmol/L) or angiotensin II 
(AII, 2 µmol/L) for 48 (n=3/ group) and 72h (n=4/group). Red ponceau (RP) was used to 
normalize s-CLU levels. Graphs show individual and median fold change in CLU levels ± IQR 
(25%-75%) relative to control cells. B: Representative western blots (left panels) and 
quantification (right panels) of active form (phosphorylated/total ratio) of Akt, GSK-3β and 
ERK1/2 in 72h ISO-treated cells compared to control cells (n=7 to 9/group). Data are expressed 
in fold change in active proteins levels relative to control cells and presented as box and whisker 
plots showing median (line) and min to max (whisker). Statistical significance was determined by 
Wilcoxon-Mann Whitney test. *P<0.05, **P<0.01 vs control cells.  
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